Hit enter to search or ESC to close
Immuneering Corporation
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
  • ABOUT
    • Our Approach
    • Team
  • PLATFORM
  • PIPELINE
  • FOR INVESTORS
  • PUBLICATIONS
  • CONTACT
    • Inquiries
    • Locations
    • Join Our Team
All Posts By

immun-ops2020

immun-ops2020 In Publications

Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay

Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique…

Read More
immun-ops2020 In Publications

Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors

Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ~2% are G12C, a specific KRAS mutation targeted by…

Read More
immun-ops2020 In Publications

Assessing reproducibility of inherited variants detected with short-read whole genome sequencing

Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant…

Read More
immun-ops2020 In Publications

FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology

Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection….

Read More
immun-ops2020 In Publications

Reporting guidelines for human microbiome research: the STORMS checklist

The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…

Read More
immun-ops2020 In Publications

Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA

Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…

Read More
immun-ops2020 In Publications

Orchestrating and sharing large multimodal data for transparent and reproducible research

Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by independent research groups, regardless of its validity. It is therefore crucial…

Read More
immun-ops2020 In Publications

Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing

The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….

Read More
immun-ops2020 In Publications

Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing

Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study…

Read More
immun-ops2020 In News

Immuneering Appoints Michael Bookman as General Counsel and Secretary

Executive with Extensive Legal Expertise in Life Sciences Strengthens Leadership Team CAMBRIDGE, Mass., July 20, 2021— Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and…

Read More
1 2 3 … 12 Next
Immuneering logo
  • ABOUT
  • PLATFORM
  • PIPELINE
  • PUBLICATIONS
  • FOR INVESTORS
  • CONTACT
  • Terms of Use
  • Privacy Policy

© 2022 Immuneering Corporation.